ISRCTN57502371已完成1 期
A Phase 1B study repurposing ATRA as stromal targeting agent along with gemcitabine and nab-paclitaxel for pancreatic cancer (STAR_PAC)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 27
研究概览
简要总结
2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32973176/ (added 26/04/2021)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- •1. Written informed consent prior to admission to this study
- •2. Age =18 years. No upper age limit
- •3. WHO performance status 0 or 1
- •4. Life expectancy =12 weeks
- •5. Histologically proven Pancreatic ductal adenocarcinoma (PDAC). Formalin-fixed, paraffin-embedded tumour sample from the primary cancer must be available for central testing. If not available or sufficient patients will be asked to undergo a US or CT guided biopsy prior to study entry to satisfy this eligibility criterion.
- •6. Locally advanced or metastatic disease which is measurable according to the Response Evaluation Criteria in Solid Tumours (RECIST v1.1)
- •7. Received no prior systemic therapy for metastatic or locally advanced disease. Prior adjuvant chemotherapy (with gemcitabine or any other drug/s) is allowed if completed at least 6 months previously.
- •8. Adequate hematologic and end-organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment:
- •8.1. Absolute Neutrophil Count =1.5 x 109/l (without granulocyte colony-stimulating factor support within 2 weeks prior to the first study treatment)
- •8.2. Platelet count =100 x 109/l (without transfusion within 2 weeks prior to the first study treatment)
- •8.3. Haemoglobin =10 g/dl (transfusion permitted to establish target haemoglobin levels prior to the first study treatment)
- •8.4. Calculated creatinine clearance (e.g. Cockcroft-Gault) =50 ml/min
- •8.5. Bilirubin level =1.5 ULN (patients with known Gilbert disease who have bilirubin levels =3 x ULN may be enrolled). Patients must be able to undergo biliary stenting if required before or, if required, during the trial
- •8.6. AST or ALT <2.5 x ULN or <5 x ULN in the presence of liver metastases
- •8.7. Alkaline phosphatase (ALP) <2.5 x ULN or <5 x ULN in the presence of liver and/or bone metastases
- •8.8. INR and aPTT =1.5 x ULN; this applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose
- •9. Female patients of child-bearing potential are eligible, provided they have a negative serum or urine pregnancy test within 7 days prior to the first dose of study treatment, preferably as close to the first dose as possible. All patients with reproductive potential must agree to use a medically acceptable method of contraception throughout the treatment period and for 1 month after discontinuation of ATRA and /or gemcitabine/nab-paclitaxel (whichever is the latest) and for 6 months after discontinuation for male patients. Acceptable methods of contraception include IUD, oral contraceptive, sub-dermal implant and double barrier (condom with a contraceptive sponge or contraceptive pessary). Micro-dosed progesterone preparations (mini-pill”) are an inadequate method of contraception during treatment with ATRA. If patients are taking this pill they should be instructed to stop and another form of contraceptive should be prescribed instead.
- •10. Able to follow protocol requirements as assessed by the Principal Investigator
排除标准
- •A patient will not be eligible for inclusion in this study if any of the following criteria apply:
- •1. Patient has known brain metastases
- •2. Patient has experienced a significant reduction in performance status between the screening/ baseline visit and within 72 hours prior to commencement of treatment as per trial protocol, as per the Investigator’s assessment
- •3. Patients with pre-existing sensory neuropathy >grade 1
- •4. History of malignancy in the last 5 years; with the exception of:
- •4.1. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible
- •4.2. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years
- •5. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
- •6. Patient has HIV, or active hepatitis B or C infection
- •7. Patient has undergone major surgery, other than diagnostic surgery (i.e., surgery to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study
- •8. Patient has a history of allergy (including soya bean or peanut allergies) or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of the products or comparator SmPC or Prescribing Information
- •9. History of connective tissue disorders (e.g., lupus, scleroderma, arteritis nodosa)
- •10. Patient with a history of interstitial lung disease, history of slowly progressive dyspnoea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
- •11. Patient with high cardiovascular risk, including, but not limited to, recent coronary stenting or myocardial infarction in the past year
- •12. History of Peripheral Artery Disease (e.g., claudication, Leo-Buerger's disease)
- •13. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity
- •14. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug =30 days prior to study entry depending on the half-life of the investigational drug and/or guidance issued by the IMP manufacturer. Please contact the STARPAC Coordinating team for further information
- •15. Patient is taking any prohibited concurrent medication, including Vitamin A supplements and is unwilling to stop use prior to and during the trial
- •16. Patient is pregnant, planning to become pregnant or breastfeeding
- •17. Patient has received a live vaccine within 4 weeks prior to receiving their first dose of study treatment
- •18. Patient is unwilling or unable to comply with study procedures, as assessed by the Principal Investigator
研究者
相似试验
进行中（未招募）
2 期
A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic CancerPancreatic CancerNCT04241276Queen Mary University of London170
招募中
不适用
Bortezomib and Tipifarnib in MDS.Myelodysplastic syndrome, Tipifarnib (ZARNESTRA), Bortezomib (VELCADE).NL-OMON26222Radboud University Nijmegen Medical Centre18
已完成
2 期
se of ARA 290 for the treatment of diabetic macular oedemaDiabetic macular oedema (DMO)Eye DiseasesISRCTN16962255Belfast Health & Social Care Trust (UK)9
已完成
2 期
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic CarcinomaAdenoid Cystic CarcinomaNCT03999684Dana-Farber Cancer Institute18
已完成
2 期
ARTSS-2: A pilot, phase IIb, randomised, multicentre, safety and activity trial of Argatroban in combination with TPA (Alteplase) Stroke StudyStrokeISRCTN51505768The University of Texas Health Science Center at Houston (USA)50